Full dose S-1 monotherapy compared to reduced dose S-1/oxaliplatin combination therapy as first-line treatment for older patients with metastatic colorectal cancer S1 eller S1/oxaliplatin
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms NORDIC9
- 23 Oct 2018 Initial results of NORDIC9 (n=156 data cut off 1st Mar 2018) presented at the 43rd European Society for Medical Oncology Congress.
- 02 Jun 2017 Results of preplanned safety analysis (n=50) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Oct 2016 Trial design is presented at 41st European Society for Medical Oncology Congress.